Mark W Frohlich has sold JUNO and made no open-market buys since Mar 2016

Mark W. Frohlich, M.D. is a biotechnology executive and medical oncologist with more than 25 years of experience developing cellular immunotherapies for cancer, and is a reported corporate insider associated with Juno Therapeutics, Inc. (JUNO).( He currently serves as chief executive officer of Indapta Therapeutics, Inc., a privately held biotechnology company developing allogeneic natural killer (NK) cell therapies for hematologic malignancies, solid tumors, and autoimmune diseases.( Dr. Frohlich has been identified in SEC-related insider-trading datasets as Mark W. Frohlich in connection with Juno Therapeutics, Inc., where his insider role has been recorded as “See Remarks,” indicating a role-specific designation rather than a standard officer title in some filings.(

Before joining Indapta, Dr. Frohlich served as executive vice president of portfolio strategy at Juno Therapeutics, where he contributed to the development of the FDA-approved CAR T‑cell therapy Breyanzi® for large B‑cell lymphoma until Juno was acquired by Celgene (later part of Bristol Myers Squibb).( Earlier, he was chief medical officer and executive vice president at Dendreon Corporation, leading the clinical and regulatory development of PROVENGE®, one of the first commercially available cancer immunotherapies.( He previously held an academic appointment as assistant adjunct professor of hematology/oncology at the University of California, San Francisco (UCSF), focusing on urologic oncology and translational research.( Dr. Frohlich earned a B.S. in Electrical Engineering and Economics from Yale College and an M.D. from Harvard Medical School, and completed internal medicine residency (including service as chief resident), a hematology/oncology fellowship, and a Howard Hughes postdoctoral fellowship at UCSF.( He also serves on the board of directors of Rigel Pharmaceuticals, Inc., where his experience in clinical development and portfolio strategy supports the company’s hematology and oncology pipeline.(

Written by Perplexity from public sources.